Release date: 2026-10-21 13:49:47 Recommended: 4
Indicated for adult patients with wild-type or variant transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and cardiovascular-related hospitalization.